| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Anesthesiology and Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287
 |
ABSTRACT |
|---|
 TOP
 ABSTRACT
 INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Obesity is a major health care problem and is associated with significant cardiovascular morbidity. Leptin, a neuroendocrine hormone released by adipose tissue, is important in modulating obesity by signaling satiety and increasing metabolism. Moreover, leptin receptors are expressed on vascular endothelial cells (ECs) and mediate angiogenesis. We hypothesized that leptin may also play an important role in vasoregulation. We investigated vasoregulatory mechanisms in the leptin-deficient obese (ob/ob) mouse model and determined the influence of leptin replacement on endothelial-dependent vasorelaxant responses. The direct effect of leptin on EC nitric oxide (NO) production was also tested by using 4,5-diaminofluorescein-2 diacetate staining and measurement of nitrate and nitrite concentrations. Vasoconstrictor responses to phenylephrine, norepinephrine, and U-46619 were markedly enhanced in aortic rings from ob/ob mice and were modulated by NO synthase inhibition. Vasorelaxant responses to ACh were markedly attenuated in mesenteric microvessels from ob/ob mice. Leptin replacement resulted in significant weight loss and reversal of the impaired endothelial-dependent vasorelaxant responses observed in ob/ob mice. Preincubation of ECs with leptin enhanced the release of NO production. Thus leptin-deficient ob/ob mice demonstrate marked abnormalities in vasoregulation, including impaired endothelial-dependent vasodilation, which is reversed by leptin replacement. These findings may be partially explained by the direct effect of leptin on endothelial NO production. These vascular abnormalities are similar to those observed in obese, diabetic, leptin-resistant humans. The ob/ob mouse may, therefore, be an excellent new model for the study of the cardiovascular effects of obesity.
nitric oxide; diabetes
| |
INTRODUCTION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
OBESITY, A MAJOR HEALTH CARE problem in the US, is associated with significant cardiovascular morbidity, including hypertension (28), atherosclerotic, and coronary artery disease (34), as well as the obesity hypoventilation syndrome and associated pulmonary hypertension (24). Significant progress has been made in the understanding of the molecular basis of obesity with the discovery of the peptide leptin (46) and its receptor (42). Leptin, a novel neuroendocrine peptide released by adipose tissue, is a satiety signal that acts through neural pathways in the hypothalamus to suppress appetite. It is also critical in modulating energy expenditure by enhancing metabolism (3, 4, 16, 35, 46). Mutations in the gene encoding leptin (46) and the leptin receptor lead to profound obesity in mice and rats (4, 5, 13, 26, 44) and in humans (32). It is now recognized, however, that most human obesity is not associated with leptin deficiency but rather with elevated leptin levels (7) and thus a presumed leptin resistance. Several mechanisms may contribute to leptin resistance, including impaired transport of leptin to the brain (6), as well as impaired leptin-receptor signal transduction (37). After cloning of the leptin receptor, isoforms were identified and found to be expressed not only in the brain but also in peripheral tissues, including lung, heart, and kidney (27, 42). Recently, leptin receptors have been shown to be expressed in human vasculature and in primary culture of human endothelial cells. Moreover, bioassays have revealed that leptin demonstrates angiogenic activity (1, 38). We hypothesized that vasoregulation may be abnormal in leptin-deficient ob/ob mice and that leptin may be important in regulating vascular function. Moreover, we hypothesized that leptin replacement would reverse these abnormalities. To test this hypothesis, we examined endothelial-dependent and -independent vasodilator function in a vessel bioassay in normal and leptin-deficient ob/ob mice, as well as nitric oxide (NO) release in endothelial cells. Our results demonstrate that 1) endothelial function is impaired in leptin-deficient mice, 2) this endothelial dysfunction is reversed after the administration of exogenous leptin, and 3) leptin directly enhances the release of NO from endothelial cells. Thus leptin may have a direct role in modulating endothelial function. Moreover, the ob/ob mouse represents a potentially excellent new model to study the complex mechanisms underlying vascular dysfunction in obesity and related disorders.
| |
METHODS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Animals
Twenty obese male C57BL/6J-Lepob mice and their weight (WT) controls, between 3 and 6 mo of age (Jackson laboratory, Bar Harbor, ME), were studied. The study was approved by the Institutional Animal Care and Use Committee and complies with the American Physiological Society guidelines.Protocols
Protocol 1. To determine the effects of the ob/ob phenotype on vascular reactivity, we studied aortic rings and mesenteric microvessels from 10 ob/ob and 10 WT control mice.
Protocol 2.
To determine the effect of leptin replacement on vascular function,
100-µl-capacity osmotic minipumps (Alza, Palo Alto, CA), filled with
mouse recombinant leptin (Amgen), were used for continuous (14-day)
administration of leptin (n = 6). Pumps were filled
with leptin (0.3 mg · kg
1 · day1) or PBS
(control; n = 6) and implanted subcutaneously in the interscapular region by using a brief halothane anesthetic. Three silk
sutures were used to close the skin, and bacitracin ointment was placed
on the wound. Animals were inspected daily to confirm satisfactory
wound healing and general health status. This method of leptin
administration has been previously used in our laboratory and results
in a mean plasma leptin concentration of ~6 ng/ml (3).
Animal weight and food intake were monitored regularly.
Aortic Vascular Reactivity
Mice were anesthetized using ketamine-acepromazine (100 and 10 mg/kg ip, respectively). The thoracic aorta was carefully dissected, rapidly removed, and placed in ice-cold oxygenated Krebs-Ringer bicarbonate solution [composition (in mM): 118.3 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 1.6 CaCl2, 25 NaHCO3, and 11.1 glucose]. The vessel was carefully cleared of loose connective tissue. The mouse aorta was cut into 1.5-mm rings and suspended between two wire stirrups (150 µm) in a myograph (Mangus) in 5 ml Krebs-Ringer (95% O2-5% CO2, pH 7.4, 37°C). One stirrup was connected to a three-dimensional micromanipulator, and the other to a force transducer (FT03, Grass Instruments). All concentration-effect curves were performed on arterial rings beginning at their optimum resting tone. This was determined by stretching arterial rings at 10-min intervals in increments of 100 mg to reach optimal tone. Optimal resting tone was the minimum level of stretch that resulted in the largest contractile response to KCl (20 mM). This has been determined previously to be 500 mg in the mouse aorta. After the arterial rings had been stretched to their optimal resting tone, the contractile response to 100 mM KCl was determined. The response to a maximal dose of KCl was used to normalize the responses to agonists across vessel rings. Dose responses to vasoconstrictors phenylephrine (PE; 109-105 M), norepinephrine (NE;
109-105 M), and U-46119
(1010-106 M) were performed in the
absence or presence of
NG-nitro-L-arginine methyl ester
(L-NAME; 104 M), a NO synthase (NOS)
inhibitor. Dose responses to the vasodilators ACh and sodium
nitroprusside (SNP; 109-105 M) were
performed after preconstriction with U-46619 (approximately EC50).
Mouse Microvessel Preparations
To determine microvessel reactivity, small arterioles were isolated from branches of the mesenteric artery under the dissecting microscope (100- to 200-µm diameter, 1-mm length). The vessels were cannulated at both ends with glass micropipettes, secured with 12-0 nylon monofilament, and placed in a microvascular chamber (Living Systems Instruments, Burlington, VT). The arteries were maintained in a no-flow state and held at a constant transluminal pressure of 40 mmHg. The chamber was superfused with control solution, maintained at 37°C with a pH of 7.4, and gassed with 95% O2-5% CO2. The chamber was then placed on the stage of an inverted microscope (×20, Nikon TMS-F). The vessel image was projected onto a video monitor, and intraluminal and wall diameter were determined continuously by a video-dimension analyzer (Living Systems Instrumentation). Cumulative dose-response curves to PE were performed. The vessels were then preconstricted to ~50% maximal contractile response (~106 M PE). Vasodilator response curves were
then generated to the endothelial-dependent and -independent
vasodilators ACh and SNP, respectively. Data were recorded by using a
MacLab system and the software CHART (AD Instruments, Mountain View, CA).
Cell Culture
Bovine pulmonary endothelial cells (BPAEC) were grown in MEM (Life Technology) supplemented with 10% fetal calf serum and 2.4 µg thymidine and were characterized as previously described (23). Cells were maintained in a humidified 37°C, 5% CO2 incubator and used between passage 14 and 16.4,5-Diaminofluorescein Staining
NO detection was performed by fluorometric examination of cells loaded with 4,5-diaminofluorescein (DAF-2) diacetate, a membrane-permeable fluorescent indicator for NO. DAF-2 has been shown to form a green-fluorescent trazolofluorescein by reacting with NO.BPAEC were grown in the 24-well plates in the medium until confluent.
Before each experiment, the medium was switched to serum-free MEM, and
the cells were incubated for 24 h. Leptin (10 7-106 M) was then added and incubated for
16 h. After being washed with Krebs-Ringer phosphate (KRP) buffer
(in mM: 120 NaCl, 4.8 KCl, 0.54 CaCl2, 1.2 MgSO4, 11 glucose, and 15.9 sodium phosphate; pH 7.2), the
cells were incubated for 1 h at 37°C in KRP containing 10 µM
DAF-2 diacetate (CalBiochem), and then the buffer was changed into KRP
containing L-arginine (1 mM) for 15 min. The cells were observed under an inverted fluorescent microscope equipped with 495-nm
excitation, 515-nm emission filters.
Measurement of Nitrite and Nitrate Concentration
BPAEC were stimulated with leptin (107-10
6 M) for 3 h. The nitrate and nitrite concentration
in the medium was measured by using a nitrite-nitrate colorimetric
method kit (Roche), according to the manufacturer's instructions.
Data Analysis
Aortic vasoconstrictor responses are expressed as a percentage of KCl maximum response. Vasodilator responses are expressed as a percentage of preconstricted tension. All microvessel vasoconstrictor responses are expressed as a percentage of intraluminal diameter. Vasodilator responses are expressed as a percentage of the preconstricted diameter. EC50 and maximal response (Emax) were calculated by using nonlinear logistic regression analysis with the software PRIZM (Graphpad). Statistical differences were determined by ANOVA or unpaired Student's t-test, as determined by the experimental design.| |
RESULTS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
The body weight of the ob/ob mice was significantly greater than that of the WT littermate controls (57 ± 1 vs. 34 ± 1 g; n = 20, P < 0.0001).
Vascular Responses in Mouse Aorta
Vasoconstrictor responses.
Vasoconstrictor responses to the agonists NE, PE, and U-46619 were
markedly enhanced in ob/ob mice as manifest by a leftward shift in the dose-response curves and an increase in Emax
(Fig. 1, Table
1). To determine whether impaired
NO production may contribute to the enhanced vasoconstrictor responses,
NE dose responses were performed in the presence of L-NAME
(105 M). L-NAME significantly enhanced the
vasoconstrictor responses to NE in both WT and ob/ob mice.
In the presence of L-NAME (105 M) (Fig. 1,
Table 1), the Emax to NE was identical in WT and ob/ob mice. However, the EC50 remained shifted
to the left in the ob/ob mice compared with WT. In fact the
EC50 to NE in ob/ob mice was identical to that
observed with NE in the presence of L-NAME in WT mice.
|
|
Vasodilator responses.
To determine the effects of leptin deficiency on endothelial-dependent
vasorelaxation, mouse aortas were preconstricted with U-46619
(~108 M), and dose-response curves were constructed to
the endothelial-dependent vasodilator ACh and the
endothelial-independent NO donor SNP. ACh resulted in significant
dose-dependent relaxation in mouse aorta. The vasorelaxant
responses in the aortic rings from ob/ob mice were
significantly attenuated compared with those from WT controls. The
Emax was 70 ± 5 vs. 91 ± 2% (n = 8, P < 0.05; Fig. 2,
Table 2). Surprisingly, vasorelaxant
responses to SNP were enhanced in aortic rings from ob/ob
mice compared with those from WT controls (log EC50:
8.1 ± 0.3 vs. 7.3 ± 0.1; n = 6, P < 0.05; Fig. 2, Table 2).
|
|
Microvascular Responses
Vessel characteristics.
Arterial segments from identical divisions of the mesenteric tree were
obtained for study. The vessels obtained from the ob/ob animals were of greater diameter than those from the WT controls (Table
3). Despite the differences in vessel
diameter, there were no differences in the vessel wall thickness
between groups.
|
Contractile responses.
PE elicited a similar response in microvessels from both control and
ob/ob animals (Table 4).
|
ACh and SNP-induced relaxation.
ACh induced concentration-dependent relaxation of the PE-preconstricted
WT mouse mesenteric microvessel. In contrast to aorta, both the
EC50 and Emax to ACh were markedly decreased in
mesenteric microvessels from ob/ob mice (Fig.
3, Table 4). SNP induced a maximal relaxant response in ob/ob microvessels that was
similar to that observed in WT controls. However, there was a
significant rightward shift in the dose-response curve (Fig.
4, Table 4).
|
|
Vascular Reactivity After Leptin Replacement
Continuous leptin infusion resulted in marked weight loss in ob/ob mice (17.9 ± 1.3 g, ~35% of body mass), whereas control (PBS) infused mice continued to gain weight (3.4 ± 1.1 g). In leptin-replacement mice, the vasorelaxant response to ACh in mesenteric microvessels demonstrated significant attenuation of the impaired endothelial-dependent vasodilatory responses observed in PBS controls (Emax: 68 ± 8 vs. 20 ± 4%; P < 0.01, n = 5; Fig. 5).
|
DAF-2 Staining and Nitrite and Nitrate Release
Incubation of BPEC with leptin (107 M) resulted in
significantly enhanced fluorescence with the addition of
L-arginine substrate that was not observed in control cells
(Fig. 6). Nitrite and nitrate measurement
in the media of cells preincubated with leptin (107 and
106 M) demonstrated significant release compared with
controls (Fig. 7). The release was
~50% of that observed with the Ca2+ ionophore A-23187.
|
|
| |
DISCUSSION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
The recent observation that leptin receptors are expressed on endothelial cells (and are important mediators of angiogenesis) led us to hypothesize that leptin could be important in modulating vasoregulatory function. We examined the vasoreactivity of vessels from control and leptin-deficient mice, as well as the direct effect of leptin on endothelial cell function, to address this hypothesis. We have demonstrated 1) enhanced vasoconstrictor responses to agonists in ob/ob mice, 2) impaired vasorelaxant responses to ACh in ob/ob mice, 3) reversal of the observed vasorelaxant responses after leptin administration, and 4) enhanced NO release from endothelial cells exposed to leptin. Our data support the concept that leptin is important in modulating vasodilator function, both directly through enhancing the release of NO from endothelial cells or indirectly by altering the hormonal milieu through reduction of obesity.
Leptin plays a central role in the regulation of energy homeostasis. There is now increasing evidence that leptin may have multiple effects potentially relevant to the cardiovascular system (28, 31), including sympathetic activation (19) and sodium excretion, as well as an increase in insulin sensitivity. Thus leptin may mediate its cardiovascular effects indirectly through the autonomic, endocrine, or renal systems. In addition, leptin may modulate cardiovascular function through receptors expressed directly on cardiovascular tissues. Our data represent the first evidence of impaired endothelial function and enhanced vasoconstrictor responses in a leptin-deficient obese mouse model. More importantly, this vascular dysfunction can be reversed with leptin replacement. These results in this specific model illustrate the importance of leptin in regulating vascular function.
The in vivo physiological effects of leptin on the cardiovascular system have been studied. For example, leptin infusions produce an increase in sympathetic nerve activity to the kidney, adrenals, and hindlimb (18, 20). This effect is not observed in obese Zucker rats with a mutation in the leptin receptor gene. This suggests that this is a direct receptor-mediated phenomenon. Despite the effects of leptin on renal sympathetic nervous system activity, acute infusions of leptin have little net effect on blood pressure, thus implying that leptin has additional counterregulatory cardiovascular effects. For example, there is preliminary evidence to suggest that leptin may induce NO-dependent vasorelaxation. Moreover, mean arterial pressure is reduced in ob/ob mice compared with their nonobese, lean littermate controls (28). This is also true in other rodent models of leptin resistance and obesity (9).
It is now established that leptin receptors are present on endothelial cells, which, when stimulated, activate specific signal transduction pathways. The OB-Rb isoform, the predominant isoform expressed on endothelial cells, stimulates tyrosine autophosphorylation (38). In addition, leptin stimulation of endothelial cells induces tyrosine phosphorylation of the transcription factor STAT-3 (signal transducer and activator of transcription-3) (38). Moreover leptin also activates the mitogen-activating protein kinase pathway (1). The role of these signaling pathways in mediating the angiogenic effects of leptin has been demonstrated. Our results demonstrating morphological differences in the microvessels from ob/ob mice could be due to these effects of leptin. In contrast, the modulating effects of leptin on pathways involved in vasoregulation have not been investigated. It is well established that cytokines acting through cytokine receptors and the janus kinase/STAT signaling pathways induce the expression of NOS (inducible NOS, NOS II) (25, 30). Moreover, leptin receptors on endothelial cells have significant homology with cytokine receptors and are considered members of the cytokine receptor superfamily. It is unknown what the effects of leptin-receptor signaling are on the expression of vasoregulatory peptides (e.g., endothelin) or enzyme systems (e.g., NOS III) that modulate vascular function. The demonstration that leptin induces the release of NO in endothelial cells in culture suggests that leptin may be coupled to NOS through an as-yet-undefined signaling pathway. Evidence for the direct effect of leptin on NO release is further strengthened by the work of Fruhbeck (11). He demonstrated that leptin induced hypotension in rats with autonomic blockade that was reversed with L-NAME. Leptin infusion was also associated with an increase in serum nitrite and nitrate concentrations. Thus leptin may modulate endothelial NO production directly.
Our results demonstrate vasoregulatory dysfunction characterized by enhanced responses to vasoconstrictors and impaired responses to endothelial-dependent vasodilators. There is a qualitative difference in the impaired vasorelaxant responses to ACh in aorta vs. mesenteric microvessels in ob/ob mice. This is characterized by an altered Emax but unchanged EC50 in aortic rings. In contrast, both Emax and EC50 were profoundly altered in mesenteric microvessels. This could be explained on the basis of the differential regulation of endothelial-derived vasoactive compounds in the microvasculature. Whereas NO is the primary endothelial-derived vasodilator in the aorta (21), other endothelial-derived factors, such as endothelium-derived hyperpolarizing factor, have been shown to be involved in the regulation of small artery tone (2) and are likely to contribute to the vasorelaxant properties of ACh (12). It is, therefore, possible that leptin deficiency may have a greater effect on the modulation of endothelium-derived hyperpolarizing factor and its associated signaling pathway in this model. The enhanced vasorelaxant responses to the direct NO donor SNP in aortic rings contrasted with the attenuated response in the mesenteric microvessels. This could be due to differential endogenous NO production in these vessel beds. Enhanced vasorelaxation to NO has been demonstrated in models in which endogenous NO production is impaired. For example, vasorelaxant response of carotid artery to SNP is augmented in endothelial NOS-deficient mice (10). An absence of NO or relative deficiency of NO could result in compensatory upregulation of downstream pathways and thus explain the enhanced response observed.
Aortic rings from wild-type mice did not demonstrate robust responses to NE or PE. This is likely due to endogenous NO release. This potential explanation is further substantiated by the robust response observed in the presence of L-NAME. Indeed, the profound response to PE and NE in rings from ob/ob mice in the absence of L-NAME suggests impaired endogenous NO production. The response of aortic rings to ACh in ob/ob mice, while significantly impaired, was not as profoundly altered as one may have predicted based on the differential contractile responses to PE. One might have predicted profound impairment of the ACh responses if there had been a significant decrement in endothelial cell NO release. This could have at least two explanations: 1) basal and stimulated NO release from endothelial cells involves different mechanisms of activation and release, and 2) NO has been demonstrated to modulate (inhibit) the sensitivity of the contractile apparatus (myosin light chain phosphorylation) to prevailing intracellular Ca2+. This is thought to be mediated by cGMP-dependent kinase regulation of myosin phosphatase (41). Thus, in our ob/ob aortic rings, the contractile apparatus might have been sensitized as a result of impaired NO release, and the response to ACh may have been facilitated.
Leptin is well known to have several important endocrine effects. These effects include increased insulin sensitivity in muscle and adipose tissue (15, 33, 39, 43), as well as complex direct and indirect interactive effects on lipid metabolism. The observed vascular effects need to be interpreted within the context of these changes. Glucose and lipid homeostasis as well as insulin have complex, interdependent effects on the vasculature. Our understanding of these phenomena has been gleaned from studies of diabetic humans as well as studies in animal models. The effects of leptin or altering these biomolecules have been thoroughly studied by Harris et al. (17). They demonstrated that 10 mg/day of leptin for 7 days could normalize insulin and glucose levels in ob/ob mice. The same doses had only transient effects on appetite and weight in lean control mice, suggesting enhanced leptin sensitivity in ob/ob mice. Thus the improvement in endothelial function with leptin replacement could be partially explained on the basis of changes in insulin sensitivity and glucose concentrations.
The deleterious effects of hyperglycemia and insulin resistance on the vasculature may be separate but additive. A number of proposed mechanisms explain the effect of hyperglycemia on endothelial function (for review, see Ref. 14). There is mounting evidence that the generation of reactive oxygen species (ROS) may play an important role in the etiology of diabetic vascular complications. This hypothesis is supported by evidence that pathways strictly associated with hypergylycemia can increase ROS production. Furthermore, exposure of endothelial cells to high glucose leads to augmented production of ROS, which may then quench NO and decrease its bioavailability. These effects may be reversed by free-radical scavengers. The effect of ROS in the ob/ob mouse is yet to be explored, but this mechanism may be involved in this model of vascular dysfunction.
Mechanisms to explain the association between insulin resistance and cardiovascular disease have been attributed to insulin's effects on vascular smooth muscle and endothelial function. Insulin enhances the release of NO (45) and increases the expression of endothelial NOS (NOS III) in the vasculature. Physiologically, insulin stimulates vasodilation by enhancing NO release (36, 40). Recently, Jiang et al. (22) have characterized selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats, which have leptin receptors that are mutated. They demonstrated a selective resistance to phosphatidylinositol 3-kinase (PI3-kinase) activation. Biologically, the activation of PI3-kinase has been linked to NO production. Thus, in our model, endothelial dysfunction may be the result of impaired PI3-kinase activation with resultant impaired NO signaling.
Obesity and insulin resistance are associated with abnormalities in lipid metabolism and hypercholesterolemia (8). The mechanisms underlying the vascular dysfunction in the setting of elevated low-density lipoproteins have been extensively investigated. These include, but are not limited to, abnormalities in the NO signaling pathway, receptor-G protein coupling, and NOS and NO bioactivity, with evidence for enhanced superoxide formation and the consequent production of the less potent dilator peroxynitrite. The effects of lipids on endothelium-dependent vasodilation can be reversed not only by reducing the elevated lipids levels, but also by provision of the NOS substrate L-arginine and by the provision of antioxidants, although the mechanism for these effects are not fully elucidated. Thus perturbations in lipid metabolism may contribute to the vascular effects observed with leptin deficiency.
Thus leptin may modulate vascular function, both directly through its interaction with endothelial leptin receptor and indirectly by its actions on sympathetic nerve activity, insulin sensitivity, and perhaps other neurohumoral metabolic pathways. We have demonstrated significant abnormalities in vascular endothelial and contractile function in vessels from the ob/ob mouse that are reversed by leptin replacement. In addition, we have demonstrated the direct effect of leptin on NO modulation in endothelial cells in culture. These pathophysiological changes may be the result of the absence of leptin or the neurohumoral milieu that is associated with leptin deficiency. The direct effects of leptin on vascular function remain to be explored in vitro. The ob/ob mouse, however, remains an excellent model for understanding the interaction among obesity, diabetes, and vascular dysfunction, because the phenotype can be readily reversed.
| |
ACKNOWLEDGEMENTS |
|---|
The authors gratefully acknowledge the technical support of Claire Levine and the secretarial support of Cheryl Dewyre.
| |
FOOTNOTES |
|---|
This work was supported by a Foundation for Anesthesia Education and Research Grant (to B. Winters) and by a National Space Biomedical Research Institute Grant (to A. Shoukas and D. E. Berkowitz).
Address for reprint requests and other correspondence: D. E. Berkowitz, Dept. of Anesthesiology and CCM, Johns Hopkins Univ. School of Medicine, 600 N. Wolfe St., Baltimore, MD 21287 (E-mail: dberkowi{at}jhmi.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 3 March 2000; accepted in final form 17 July 2000.
| |
REFERENCES |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
1.
Bouloumie, A,
Drexler HCA,
Lofontan M,
and
Busse R.
Leptin, the product of Ob gene promotes angiogenesis.
Circ Res
83:
1059-1066,
1999
2.
Brayden, JE,
and
Nelson MT.
Regulation of arterial tone by activation of calcium-dependent potassium channels.
Science
256:
532-535,
1992
3.
Breslow, MJ,
Min-Lee K,
Brown DR,
Chacko VP,
Palmer D,
and
Berkowitz DE.
Effect of leptin deficiency on metabolic rate in ob/ob mice.
Am J Physiol Endocrinol Metab
276:
E443-E449,
1999
4.
Campfield, LA,
Smith FJ,
and
Burn P.
The OB protein (leptin) pathway-a link between adipose tissue mass and central neural networks.
Horm Metab Res
28:
619-632,
1996[Web of Science][Medline].
5.
Caprio, S,
Tamborlane WV,
Silver D,
Robinson C,
Leibel R,
McCarthy S,
Grozman A,
Belous A,
Maggs D,
and
Sherwin RS.
Hyperleptinemia: an early sign of juvenile obesity. Relations to body fat depots and insulin concentrations.
Am J Physiol Endocrinol Metab
271:
E626-E630,
1996
6.
Caro, JF,
Kolaczynski JW,
Nyce MR,
Ohannesian JP,
Opentanova I,
Goldman WH,
Lynn RB,
Zhang PL,
Sinha MK,
and
Considine RV.
Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance.
Lancet
348:
159-161,
1996[Web of Science][Medline].
7.
Considine, RV,
Sinha MK,
Heiman ML,
Kriauciunas A,
Stephens TW,
Nyce MR,
Ohannesian JP,
Marco CC,
McKee LJ,
Bauer TL,
and
Caro JF.
Serum immunoreactive-leptin concentrations in normal-weight and obese humans (see comments).
N Engl J Med
334:
292-295,
1996
8.
Dart, AM,
and
Chin-Dusting JP.
Lipids and the endothelium.
Cardiovasc Res
43:
308-322,
1999
9.
Ernsberger, P,
Koletsky RJ,
Collins LA,
and
Bedol D.
Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent.
Cardiovasc Drugs Ther
10:
275-282,
1996.
10.
Faraci, FM,
Sigmund CD,
Shesely EG,
Maeda N,
and
Heistad DD.
Responses of carotid artery in mice deficient in expression of the gene for endothelial NO synthase.
Am J Physiol Heart Circ Physiol
274:
H564-H570,
1998
11.
Fruhbeck, G.
Pivotal role of nitric oxide in the control of blood pressure after leptin administration.
Diabetes
48:
903-908,
1999[Abstract].
12.
Garland, CJ,
Plane F,
Kemp BK,
and
Cocks TM.
Endothelium-dependent hyperpolarization: a role in the control of vascular tone.
Trends Pharmacol Sci
16:
23-30,
1995[Medline]. [Corrigenda. Trends Pharmacol Sci 16: May 1995, p. 177.]
13.
Ghilardi, N,
Ziegler S,
Wiestner A,
Stoffel R,
Heim MH,
and
Skoda RC.
Defective STAT signaling by the leptin receptor in diabetic mice.
Proc Natl Acad Sci USA
93:
6231-6235,
1996
14.
Giugliano, D,
Ceriello A,
and
Paolisso G.
Oxidative stress and diabetic vascular complications (see comments).
Diabetes Care
19:
257-267,
1996[Abstract].
15.
Haffner, SM,
Miettinen H,
Mykkanen L,
Karhapaa P,
Rainwater DL,
and
Laakso M.
Leptin concentrations and insulin sensitivity in normoglycemic men.
Int J Obes Relat Metab Disord
21:
393-399,
1997[Web of Science][Medline].
16.
Halaas, JL,
Boozer C,
Blair-West J,
Fidahusein N,
Denton DA,
and
Friedman JM.
Physiological response to long-term peripheral and central leptin infusion in lean and obese mice.
Proc Natl Acad Sci USA
94:
8878-8883,
1997
17.
Harris, RB,
Zhou J,
Redmann SM,
Smagin GM,
Smith SR,
Rodgers E,
and
Zachwieja JJ.
A leptin dose response study in obese (ob/ob) and lean (+/?) mice.
Endocrinology
139:
8-19,
1998
18.
Haynes, WG,
Morgan DA,
Walsh SA,
Mark AL,
and
Sivitz WI.
Receptor-mediated regional sympathetic nerve activation by leptin.
J Clin Invest
100:
270-278,
1997[Web of Science][Medline].
19.
Haynes, WG,
Morgan DA,
Walsh SA,
Sivitz WI,
and
Mark AL.
Cardiovascular consequences of obesity: role of leptin.
Clin Exp Pharmacol Physiol
25:
65-69,
1998[Web of Science][Medline].
20.
Haynes, WG,
Sivitz WI,
Morgan DA,
Walsh SA,
and
Mark AL.
Sympathetic and cardiorenal actions of leptin.
Hypertension
30:
619-623,
1997
21.
Huang, PL,
Huang Z,
Mashimo H,
Bloch KD,
Moskowitz MA,
Bevan JA,
and
Fishman MC.
Hypertension in mice lacking the gene for endothelial nitric oxide synthase (see comments).
Nature
377:
239-242,
1995[Medline].
22.
Jiang, ZY,
Lin YW,
Clemont A,
Feener EP,
Hein KD,
Igarashi M,
Yamauchi T,
White MF,
and
King GL.
Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats.
J Clin Invest
104:
447-457,
1999[Web of Science][Medline].
23.
Johns, RA,
Peach MJ,
Linden J,
and
Tichotsky A.
NG-monomethyl L-arginine inhibits endothelium-derived relaxing factor-stimulated cyclic GMP accumulation in cocultures of endothelial and vascular smooth muscle cells by an action specific to the endothelial cell.
Circ Res
67:
979-985,
1990
24.
Kessler, R,
Chaouat A,
Weitzenblum E,
Oswald M,
Ehrhart M,
Apprill M,
and
Krieger J.
Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences.
Eur Respir J
9:
787-794,
1996[Abstract].
25.
Kleinert, H,
Wallerath T,
Fritz G,
Ihrig-Biedert I,
Rodriguez-Pascual F,
Geller DA,
and
Forstermann U.
Cytokine induction of NO synthase II in human DLD-1 cells: roles of the JAK-STAT, AP-1 and NF-
B-signaling pathways.
Br J Pharmacol
125:
193-201,
1998[Web of Science][Medline].
26.
Lee, GH,
Proenca R,
Montez JM,
Carroll KM,
Darvishzadeh JG,
Lee JI,
and
Friedman JM.
Abnormal splicing of the leptin receptor in diabetic mice.
Nature
379:
632-635,
1996[Medline].
27.
Lollmann, B,
Gruninger S,
Stricker-Krongrad A,
and
Chiesi M.
Detection and quantification of the leptin receptor splice variants Ob-Ra, b, and e in different mouse tissues.
Biochem Biophys Res Commun
238:
648-652,
1997[Web of Science][Medline].
28.
Mark, AL,
Correia M,
Morgan DA,
Shaffer RA,
and
Haynes WG.
State-of-the-art-lecture: obesity-induced hypertension: new concepts from the emerging biology of obesity.
Hypertension
33:
537-541,
1999
30.
Marrero, MB,
Venema VJ,
He H,
Caldwell RB,
and
Venema RC.
Inhibition by the JAK/STAT pathway of IFN
- and LPS-stimulated nitric oxide synthase induction in vascular smooth muscle cells.
Biochem Biophys Res Commun
252:
508-512,
1998[Web of Science][Medline].
31.
Mikhail, N,
Golub MS,
and
Tuck ML.
Obesity and hypertension.
Prog Cardiovasc Dis
42:
39-58,
1999[Web of Science][Medline].
32.
Montague, CT,
Farooqi IS,
Whitehead JP,
Soos MA,
Rau H,
Wareham NJ,
Sewter CP,
Digby JE,
Mohammed SN,
Hurst JA,
Cheetham CH,
Earley AR,
Barnett AH,
Prins JB,
and
O'Rahilly S.
Congenital leptin deficiency is associated with severe early-onset obesity in humans.
Nature
387:
903-908,
1997[Medline].
33.
Muller, G,
Ertl J,
Gerl M,
and
Preibisch G.
Leptin impairs metabolic actions of insulin in isolated rat adipocytes.
J Biol Chem
272:
10585-10593,
1997
34.
Must, A,
Spadano J,
Coakley EH,
Field AE,
Colditz G,
and
Dietz WH.
The disease burden associated with overweight and obesity.
JAMA
282:
1523-1529,
1999
35.
Pelleymounter, MA,
Cullen MJ,
Baker MB,
Hecht R,
Winters D,
Boone T,
and
Collins F.
Effects of the obese gene product on body weight regulation in ob/ob mice (see comments).
Science
269:
540-543,
1995
36.
Scherrer, U,
Randin D,
Vollenweider P,
Vollenweider L,
and
Nicod P.
Nitric oxide release accounts for insulin's vascular effects in humans.
J Clin Invest
94:
2511-2515,
1994.
37.
Schwartz, MW,
Woods SC,
Porte D,
Seeley RJ,
and
Baskin DG.
Central nervous system control of food intake.
Nature
404:
661-671,
2000[Medline].
38.
Sierra-Honigmann, MR,
Nath AK,
Murakami C,
Garcia-Cardena G,
Papapetropoulos A,
Sessa WC,
Madge LA,
Schechner JS,
Schwabb MB,
Polverini PJ,
and
Flores-Riveros JR.
Biological action of leptin as an angiogenic factor.
Nature
281:
1683-1686,
1998.
39.
Sivitz, WI,
Walsh SA,
Morgan DA,
Thomas MJ,
and
Haynes WG.
Effects of leptin on insulin sensitivity in normal rats.
Endocrinology
138:
3395-3401,
1997
40.
Steinberg, HO,
Brechtel G,
Johnson A,
Fineberg N,
and
Baron AD.
Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release.
J Clin Invest
94:
1172-1179,
1994.
41.
Surks, HK,
Mochizuki N,
Kasai Y,
Georgescu SP,
Tang KM,
Ito M,
Lincoln TM,
and
Mendelsohn ME.
Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase I
.
Science
286:
1583-1587,
1999
42.
Tartaglia, LA,
Dembski M,
Weng X,
Deng N,
Culpepper J,
Devos R,
Richards GJ,
Campfield LA,
Clark FT,
Deeds J,
Identification and expression cloning of a leptin receptor, OB-R.
Cell
83:
1263-1271,
1995[Web of Science][Medline].
43.
Turpeinen, AK,
Haffner SM,
Louheranta AM,
Niskanen LK,
Miettinen H,
and
Uusitupa MI.
Serum leptin in subjects with impaired glucose tolerance in relation to insulin sensitivity and first-phase insulin response.
Int J Obes Relat Metab Disord
21:
284-287,
1997[Web of Science][Medline].
44.
Wu-Peng, XS,
Chua SC, Jr,
Okada N,
Liu SM,
Nicolson M,
and
Leibel RL.
Phenotype of the obese Koletsky (f) rat due to Tyr763Stop mutation in the extracellular domain of the leptin receptor (Lepr): evidence for deficient plasma-to-CSF transport of leptin in both the Zucker and Koletsky obese rat.
Diabetes
46:
513-518,
1997[Abstract].
45.
Zeng, G,
and
Quon MJ.
Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells.
J Clin Invest
98:
894-898,
1996[Web of Science][Medline].
46.
Zhang, Y,
Proenca R,
Maffei M,
Barone M,
Leopold L,
and
Friedman JM.
Positional cloning of the mouse obese gene and its human homologue.
Nature
372:
425-432,
1994[Medline].
This article has been cited by other articles:
|
|
 |
|
  C. M. Maya-Monteiro, P. E. Almeida, H. D'Avila, A. S. Martins, A. P. Rezende, H. Castro-Faria-Neto, and P. T. Bozza Leptin Induces Macrophage Lipid Body Formation by a Phosphatidylinositol 3-Kinase- and Mammalian Target of Rapamycin-dependent Mechanism J. Biol. Chem., January 25, 2008; 283(4): 2203 - 2210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Kearney, E. R. Duncan, M. Kahn, and S. B. Wheatcroft Insulin resistance and endothelial cell dysfunction: studies in mammalian models Exp Physiol, January 1, 2008; 93(1): 158 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Lim, H. K. Lim, S. Ryoo, A. Benjo, K. Shuleri, V. Miriel, E. Baraban, A. Camara, K. Soucy, D. Nyhan, et al. Mitochondrial arginase II constrains endothelial NOS-3 activity Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3317 - H3324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Yang and L. A. Barouch Leptin Signaling and Obesity: Cardiovascular Consequences Circ. Res., September 14, 2007; 101(6): 545 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Katagiri, T. Yamada, and Y. Oka Adiposity and Cardiovascular Disorders: Disturbance of the Regulatory System Consisting of Humoral and Neuronal Signals Circ. Res., July 6, 2007; 101(1): 27 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Knudson, G. M. Dick, and J. D. Tune Adipokines and Coronary Vasomotor Dysfunction Experimental Biology and Medicine, June 1, 2007; 232(6): 727 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rodriguez, A. Fortuno, J. Gomez-Ambrosi, G. Zalba, J. Diez, and G. Fruhbeck The Inhibitory Effect of Leptin on Angiotensin II-Induced Vasoconstriction in Vascular Smooth Muscle Cells Is Mediated via a Nitric Oxide-Dependent Mechanism Endocrinology, January 1, 2007; 148(1): 324 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Schindler, J. Cardenas, J. O. Prior, A. D. Facta, M. C. Kreissl, X.-L. Zhang, J. Sayre, M. Dahlbom, J. Licinio, and H. R. Schelbert Relationship Between Increasing Body Weight, Insulin Resistance, Inflammation, Adipocytokine Leptin, and Coronary Circulatory Function J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1188 - 1195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Dong, X Zhang, X Yang, L B Esberg, H Yang, Z Zhang, B Culver, and J Ren Impaired cardiac contractile function in ventricular myocytes from leptin-deficient ob/ob obese mice J. Endocrinol., January 1, 2006; 188(1): 25 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Knudson, U. D. Dincer, C. Zhang, A. N. Swafford Jr., R. Koshida, A. Picchi, M. Focardi, G. M. Dick, and J. D. Tune Leptin receptors are expressed in coronary arteries, and hyperleptinemia causes significant coronary endothelial dysfunction Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H48 - H56. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-F. Huang, B. Wang, X.-F. Yang, Q. Luo, and J.-Z. Sheng Nitric Oxide Mediates Inhibitory Effect of Leptin on Insulin-Like Growth Factor I Augmentation of 17{beta}-Estradiol Production in Human Granulosa Cells Biol Reprod, January 1, 2005; 72(1): 102 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Schirmer, I. R. Buschmann, M. M. Jost, I. E. Hoefer, S. Grundmann, J.-P. Andert, S. Ulusans, C. Bode, J. J. Piek, and N. van Royen Differential effects of MCP-1 and leptin on collateral flow and arteriogenesis Cardiovasc Res, November 1, 2004; 64(2): 356 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Stephenson, J. Tunstead, A. Tsai, R. Gordon, S. Henderson, and H. M. Dansky Neointimal Formation After Endovascular Arterial Injury Is Markedly Attenuated in db/db Mice Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): 2027 - 2033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Barouch, D. E. Berkowitz, R. W. Harrison, C. P. O'Donnell, and J. M. Hare Disruption of Leptin Signaling Contributes to Cardiac Hypertrophy Independently of Body Weight in Mice Circulation, August 12, 2003; 108(6): 754 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Cooke and R. K. Oka Does Leptin Cause Vascular Disease? Circulation, October 8, 2002; 106(15): 1904 - 1905. [Full Text] [PDF]
|
|
|
|
|
|
M. Baratta, R. Saleri, G. L. Mainardi, D. Valle, A. Giustina, and C. Tamanini Leptin Regulates GH Gene Expression and Secretion and Nitric Oxide Production in Pig Pituitary Cells Endocrinology, February 1, 2002; 143(2): 551 - 557. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
